The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial

Dahlöf, 2010, Cardiovascular disease risk factors: epidemiology and risk assessment, Am. J. Cardiol., 105, 3A, 10.1016/j.amjcard.2009.10.007 Crea, 2013, Pathogenesis of acute coronary syndromes, J. Am. Coll. Cardiol., 61, 1, 10.1016/j.jacc.2012.07.064 Ridker, 2005, C-Reactive protein levels and outcomes after statin therapy, N. Engl. J. Med., 352, 20, 10.1056/NEJMoa042378 Nissen, 2005, Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease, N. Engl. J. Med., 352, 29, 10.1056/NEJMoa042000 Rubenfire, 2010, Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events, Am. J. Med., 123, 892, 10.1016/j.amjmed.2010.03.024 Libby, 2002, Inflammation in atherosclerosis, Nature, 420, 868, 10.1038/nature01323 Charo, 2011, Anti-inflammatory therapeutics for the treatment of atherosclerosis, Nat. Rev. Drug Discov., 10, 365, 10.1038/nrd3444 Muslin, 2008, MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets, Clin. Sci. (Lond.), 115, 203, 10.1042/CS20070430 Kaminska, 2005, MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits, Biochim.Biophys. Acta (BBA) – Proteins Proteomics, 1754, 253, 10.1016/j.bbapap.2005.08.017 Cheriyan, 2011, Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia, Circulation, 123, 515, 10.1161/CIRCULATIONAHA.110.971986 Proctor, 2008, Requirement for p38 mitogen-activated protein kinase activity in neointima formation after vascular injury, Circulation, 118, 658, 10.1161/CIRCULATIONAHA.107.734848 Rudd, 2002, Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography, Circulation, 105, 2708, 10.1161/01.CIR.0000020548.60110.76 Tawakol, 2006, In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients, J. Am. Coll. Cardiol., 48, 1818, 10.1016/j.jacc.2006.05.076 Tahara, 2006, Simvastatin attenuates plaque inflammation, J. Am. Coll. Cardiol., 48, 1825, 10.1016/j.jacc.2006.03.069 Wu, 2011, The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers, Eur. J. Nucl. Med. Mol. Imaging, 39, 399, 10.1007/s00259-011-1994-7 Vucic, 2011, Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging, JACC Cardiovasc. Imaging, 4, 1100, 10.1016/j.jcmg.2011.04.020 Vucic, 2012, Regression of inflammation in atherosclerosis by the LXR agonist R211945, JACC Cardiovasc Imaging, 5, 819, 10.1016/j.jcmg.2011.11.025 Mizoguchi, 2011, Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes, JACC Cardiovasc Imaging, 4, 1110, 10.1016/j.jcmg.2011.08.007 Elkhawad, 2012, Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis, JACC Cardiovasc Imaging, 5, 911, 10.1016/j.jcmg.2012.02.016 Liu, 2010, Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl- N-propylpyrrolo[1,2- f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP Kinase inhibitor for the treatment of inflammatory diseases, J. Med. Chem., 53, 6629, 10.1021/jm100540x Tawakol, 2006, In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients, J. Am. Coll. Cardiol., 48, 1818, 10.1016/j.jacc.2006.05.076 Rudd, 2007, 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible, J. Am. Coll. Cardiol., 50, 892, 10.1016/j.jacc.2007.05.024 Fayad, 2011, Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial, Lancet, 378, 1547, 10.1016/S0140-6736(11)61383-4 Tawakol, 2014, Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-Fluorodeoxyglucose-PET imaging, J. Am. Coll. Cardiol., 63, 86, 10.1016/j.jacc.2013.07.050 Seimon, 2009, Macrophage deficiency of p38α MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice, J. Clin. Investig., 119, 886 Kardakaris, 2011, Endothelial and macrophage-specific deficiency Of P38α MAPK does not affect the pathogenesis of atherosclerosis in ApoE−/− mice, PLoS One, 6, e21055, 10.1371/journal.pone.0021055 Tawakol, 2013, Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of A multi-center FDG-PET/CT feasibility study, J. Am. Coll. Cardiol., 62, 909, 10.1016/j.jacc.2013.04.066